

WHO Expert Committee on Drug Dependence

Thirty-fifth Report

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
9 7 3

WHO Expert Committee on Drug Dependence

Thirty-fifth Report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Drug Dependence : thirty-fifth report.

(WHO technical report series ; no. 973)

1.Psychotropic drugs - classification. 2.Drug evaluation. 3.Drug and narcotic control. 4.Drugs, Essential – supply and distribution. 5.International cooperation. 6.Guideline. I.World Health Organization. II.WHO Expert Committee on Drug Dependence. Meeting (35th: 2012: Hammamet, Tunisia). III.Series.

ISBN 978 92 4 120973 1

(NLM classification: WM 270)

ISSN 0250-8737

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Canada

Contents

Abbreviations	vi
Introduction	1
1. Revision of guidelines	3
2. Work of international bodies concerned with controlled substances	4
3. Critical review of psychoactive substances	5
3.1 Substance recommended for change in scheduling	6
γ-Hydroxybutyric acid (GHB)	6
3.2 Other substance critically reviewed	8
Ketamine (INN)	8
4. Pre-review of psychoactive substances	10
4.1 Dextromethorphan (pINN)	10
4.2 Tapentadol (INN)	11
4.3 Piperazines	12
4.3.1 N-Benzylpiperazine (BZP)	12
4.3.2 1-(3-Trifluoromethylphenyl)piperazine (TFMPP)	12
4.3.3 1-(3-Chlorophenyl)piperazine (mCPP)	13
4.3.4 1-(4-Methoxyphenyl)piperazine (MeOPP)	13
4.3.5 1-(3,4-Methylenedioxybenzyl)piperazine (MDBP)	14
4.4 γ-Butyrolactone (GBL)	14
4.5 1,4-Butanediol (1,4-BD)	15
5. Issues identified for consideration at future ECDD meetings	16
6. Other matters	17
6.1 Use of terms	17
6.2 Use of pharmacovigilance data for the assessment of abuse and dependence potential	17
6.3 Balancing medical availability and prevention of abuse of medicines manufactured from controlled substances	18
6.4 Improving the process for substance evaluation	20
Acknowledgements	20
References	20
Annex	
Developments in terminology: the drug treaties, scheduling criteria, and diagnostic terms	23

WHO Expert Committee on Drug Dependence

Hammamet, Tunisia, 4–8 June, 2012

Members¹

Professor M.S. Bourin, Professor, Neurobiologie de l'anxiété et de la dépression, Faculté de Médecine, Nantes, France

Dr B. Brands, Senior Science Adviser and Senior Scientist, Health Canada; Affiliate Scientist, Centre for Addiction and Mental Health, Toronto, Canada; Assistant Professor, Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada (*Rapporteur*)

Professor J. Harro, Director, Estonian Centre of Behavioural and Health Sciences, Department of Psychology, University of Tartu, Tartu, Estonia

Mrs L. De Lima, Executive Director, International Association for Hospice and Palliative Care, Houston, TX, USA (*Co-chair*)

Mrs C.L.C. MunyimbaYeta, Director, Inspectorate and Licensing, Pharmaceutical Regulatory Authority, Lusaka, Zambia

Dr E.J.M. Pennings, Biochemist and Toxicologist, Oegstgeest, The Netherlands

Professor J.B. Saunders, Professor and Consultant Physician, University of Queensland, Herston, Queensland; University of Sydney, Sydney, New South Wales, Australia

Professor T. Suzuki, Professor, Department of Toxicology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan

Professor A.A. Uchtenhagen, Professor, Institut für Sucht- und Gesundheitsforschung, University of Zurich, Zurich, Switzerland

Dr V. Verachai, Director, Princess Mother National Institute on Drug Abuse Treatment, Department of Medical Services, Thailand

Professor W. Wieniawski, Polish Pharmaceutical Society, Warsaw, Poland (*Chair*)

¹ Unable to attend: Dr A. Dhawan, Associate Professor, National Drug Dependence Treatment Centre, Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India and Dr M.E. Medina-Mora, Directora General, Instituto Nacional de Psiquiatría Ramón de la Fuente, Calz. Mexico.

Representatives of other organizations

International Narcotics Control Board (INCB)

Mrs M. Ehrenfeldner, Chief, Psychotropics Control Section, International Narcotics Control Board Secretariat, INCB, Vienna, Austria

Dr G. Korchagina, Member; Professor, Deputy Director on Research, National Research Center on Addiction, Moscow, Russian Federation

United Nations Office on Drugs and Crime (UNODC)

Dr J. Tettesy, Chief, Laboratory and Scientific Section, UNODC, Vienna, Austria

World Self-Medication Industry (WSMI)

Professor R.L. Balster, Director, Institute for Drug and Alcohol Studies, Butler Professor of Pharmacology and Toxicology, Research Professor of Psychology and Psychiatry, Virginia Commonwealth University, Richmond, VA, USA

Secretariat

Professor P.M. Beardsley, Professor of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA (*Temporary Adviser*)

Dr W. Best, Coordinating/Specialist Senior Inspector, Healthcare Inspectorate, the Hague, The Netherlands (*Temporary Adviser*)

Mrs C. Bodenschatz, Independent Consultant, Basel, Switzerland (*Temporary Adviser*)

Mr N. Dasgupta, Research Associate, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA (*Temporary Adviser*)

Dr R. Edwards, Uppsala Monitoring Centre, Uppsala, Sweden (*Temporary Adviser*)

Dr E. Mathai, Technical Officer, Medicine Access and Rational Use, Department of Essential Medicines and Health Products, WHO, Geneva, Switzerland

Dr V.B. Poznyak, Coordinator, Management of Substance Abuse, Department of Mental Health and Substance Abuse, WHO, Geneva, Switzerland

Professor R.G.W. Room, Professor, School of Population Health, University of Melbourne; Director, Centre for Alcohol Policy Research, Turning Point Alcohol and Drug Centre, Fitzroy, Victoria, Australia (*Temporary Adviser*)

Dr W. Scholten, Team Leader, Access to Controlled Medicines, Medicine Access and Rational Use, Department of Essential Medicines and Health Products, WHO, Geneva, Switzerland (*Secretary*)

Abbreviations

1,4-BD	1,4-butanediol
AIDS	acquired immunodeficiency syndrome
BZP	N-benzylpiperazine
CND	Commission on Narcotic Drugs
ECDD	Expert Committee on Drug Dependence
ECOSOC	Economic and Social Council
EU	European Union
GABA	γ -aminobutyric acid
GBL	γ -butyrolactone
GHB	γ -hydroxybutyric acid
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HIV	human immunodeficiency virus
ICD	International Classification of Diseases
INCB	International Narcotics Control Board
INN	International Nonproprietary Name
LAAM	levacetylmethadol
LSD	lysergic acid diethylamide
mCPP	1-(3-chlorophenyl)piperazine
MeOPP	1-(4-methoxyphenyl)piperazine
MDBP	1-(3,4-methylenedioxybenzyl)piperazine
MDBZP	1-(3,4-methylenedioxybenzyl)piperazine
MDMA	methylenedioxymethamphetamine
NMDA	N-methyl-D-aspartate
---	---

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28202

